Drug intelligence / Profile preview

DLV avian coccidiosis vaccine

Development stage: Unknown
Lead developer: Xi'an Tianxing Bio-Pharmaceutical
Modality: Vaccines & Immunotherapeutics
Administration: Oral

Overview

**DLV avian coccidiosis vaccine** is a trivalent veterinary vaccine for prevention of avian coccidiosis in poultry. It is described publicly as a domestically produced avian coccidiosis vaccine and is manufactured in China by Xi'an Tianxing Biopharmaceutical. The product is intended to induce protective immunity against coccidial protozoa of the genus *Eimeria*, which cause intestinal disease, impaired growth, reduced feed conversion, and mortality in chickens.

Brand names: DLV
Other names: DLV Avian Coccidiosis Trivalent Vaccine

Beyond the preview

Go deeper on DLV avian coccidiosis vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DLV avian coccidiosis vaccine.

Explore the full profile